Pag-aaral pangklinika para sa Leukemia sa Tennessee
14 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa Tennessee.
Mga Lungsod sa Tennessee
Opisyal na teksto ng pag-aaral (English)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 12, Nashville
Nagre-recruitPhase 3
Edad 18 hanggang 71 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07504458A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- St. Jude Children's Research Hospital, Memphis
Nagre-recruitPhase 1
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06810583Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07284433Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT06034275Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.